{"transactions":[{"id":4635422,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":55791,"kind":"person","name":"Sandler Alan B.","position":1,"cik":"0001835966","reported_name":"Sandler Alan B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-10-02T02:00:04.000Z","date":"2026-09-29","kind":"exercise","planned":true,"acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Twenty-five percent of the total shares subject to the option will vest on the first year anniversary measured from September 29, 2025 (the \"Vesting Commencement Date\") and one forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary of the Vesting Commencement Date thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":161300,"derivative":{"exercise_price":58.84,"expiration_date":"2035-11-01","underlying":"Common Stock","underlying_shares":167300},"source":{"system":"sec-edgar","filing":"0001835966-26-000008","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000183596626000008/ownership.xml","form_type":"4"}},{"id":4635421,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":55791,"kind":"person","name":"Sandler Alan B.","position":1,"cik":"0001835966","reported_name":"Sandler Alan B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2026-10-02T02:00:04.000Z","date":"2026-09-29","kind":"sale","planned":true,"acquired":false,"shares":301,"price":204.7224,"value":61621.4424,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The transaction was executed in multiple trades at prices ranging from $204.43 to $204.83, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"Includes 52,350 restricted stock units."}],"balance_after":52559,"source":{"system":"sec-edgar","filing":"0001835966-26-000008","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000183596626000008/ownership.xml","form_type":"4"}},{"id":4635420,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":55791,"kind":"person","name":"Sandler Alan B.","position":1,"cik":"0001835966","reported_name":"Sandler Alan B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2026-10-02T02:00:04.000Z","date":"2026-09-29","kind":"sale","planned":true,"acquired":false,"shares":1199,"price":203.9074,"value":244484.9726,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transaction was executed in multiple trades at prices ranging from $203.42 to $204.29, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":52860,"source":{"system":"sec-edgar","filing":"0001835966-26-000008","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000183596626000008/ownership.xml","form_type":"4"}},{"id":4635419,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":55791,"kind":"person","name":"Sandler Alan B.","position":1,"cik":"0001835966","reported_name":"Sandler Alan B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2026-10-02T02:00:04.000Z","date":"2026-09-29","kind":"sale","planned":true,"acquired":false,"shares":1000,"price":202.8127,"value":202812.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction was executed in multiple trades at prices ranging from $202.42 to $203.34, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":54059,"source":{"system":"sec-edgar","filing":"0001835966-26-000008","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000183596626000008/ownership.xml","form_type":"4"}},{"id":4635418,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":55791,"kind":"person","name":"Sandler Alan B.","position":1,"cik":"0001835966","reported_name":"Sandler Alan B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2026-10-02T02:00:04.000Z","date":"2026-09-29","kind":"sale","planned":true,"acquired":false,"shares":1609,"price":201.7239,"value":324573.7551,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction was executed in multiple trades at prices ranging from $201.41 to $202.16, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":55059,"source":{"system":"sec-edgar","filing":"0001835966-26-000008","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000183596626000008/ownership.xml","form_type":"4"}},{"id":4635417,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":55791,"kind":"person","name":"Sandler Alan B.","position":1,"cik":"0001835966","reported_name":"Sandler Alan B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2026-10-02T02:00:04.000Z","date":"2026-09-29","kind":"sale","planned":true,"acquired":false,"shares":2200,"price":200.8188,"value":441801.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades at prices ranging from $200.41 to $201.38, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":56668,"source":{"system":"sec-edgar","filing":"0001835966-26-000008","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000183596626000008/ownership.xml","form_type":"4"}},{"id":4635416,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":55791,"kind":"person","name":"Sandler Alan B.","position":1,"cik":"0001835966","reported_name":"Sandler Alan B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2026-10-02T02:00:04.000Z","date":"2026-09-29","kind":"exercise","planned":true,"acquired":true,"shares":6000,"price":58.84,"value":353040.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026."}],"balance_after":58868,"source":{"system":"sec-edgar","filing":"0001835966-26-000008","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000183596626000008/ownership.xml","form_type":"4"}},{"id":4624334,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":55791,"kind":"person","name":"Sandler Alan B.","position":1,"cik":"0001835966","reported_name":"Sandler Alan B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2026-09-18T22:06:03.000Z","date":"2026-09-16","kind":"sale","planned":true,"acquired":false,"shares":336,"price":199.3032,"value":66965.8752,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on June 13, 2026 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 52,350 restricted stock units."}],"balance_after":52868,"source":{"system":"sec-edgar","filing":"0001835966-26-000006","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000183596626000006/ownership.xml","form_type":"4"}},{"id":4624333,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":55791,"kind":"person","name":"Sandler Alan B.","position":1,"cik":"0001835966","reported_name":"Sandler Alan B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2026-09-18T22:06:03.000Z","date":"2026-09-16","kind":"sale","planned":true,"acquired":false,"shares":5,"price":194.9589,"value":974.7945,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on June 13, 2026 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 209 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2026."}],"balance_after":53204,"source":{"system":"sec-edgar","filing":"0001835966-26-000006","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000183596626000006/ownership.xml","form_type":"4"}},{"id":934338,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":55791,"kind":"person","name":"Sandler Alan B.","position":1,"cik":"0001835966","reported_name":"Sandler Alan B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-01-21T21:30:17.000Z","date":"2026-01-20","kind":"grant","planned":false,"acquired":true,"shares":10100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the option vest in 12 equal monthly installments beginning on February 20, 2026."}],"balance_after":10100,"derivative":{"exercise_price":1.32,"expiration_date":"2036-01-19","underlying":"Common Stock","underlying_shares":10100},"source":{"system":"sec-edgar","filing":"0001193125-26-018028","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000119312526018028/ownership.xml","form_type":"4"}},{"id":1081821,"issuer":{"id":77243,"kind":"organization","name":"Elevation Oncology, Inc.","symbol":"ELEV"},"owners":[{"id":55791,"kind":"person","name":"Sandler Alan B.","position":1,"cik":"0001835966","reported_name":"Sandler Alan B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-24T16:40:04.000Z","date":"2025-07-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of June 8, 2025, by and among Elevation Oncology, Inc. (the \"Issuer\"), Concentra Biosciences, LLC (\"Parent\") and Concentra Merger Sub VI, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On July 23, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $0.36 per Share in cash (the \"Cash Amount\"), and (ii) one non-transferable contractual contingent value right (each, a \"CVR\"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the \"Offer Price\"). [continues to Footnote 2]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"[continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding, it was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":0.3051,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001415889-25-020241","document":"form4-07242025_040701.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1783032/000141588925020241/form4-07242025_040701.xml","form_type":"4"}},{"id":1081820,"issuer":{"id":77243,"kind":"organization","name":"Elevation Oncology, Inc.","symbol":"ELEV"},"owners":[{"id":55791,"kind":"person","name":"Sandler Alan B.","position":1,"cik":"0001835966","reported_name":"Sandler Alan B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-24T16:40:04.000Z","date":"2025-07-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of June 8, 2025, by and among Elevation Oncology, Inc. (the \"Issuer\"), Concentra Biosciences, LLC (\"Parent\") and Concentra Merger Sub VI, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On July 23, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $0.36 per Share in cash (the \"Cash Amount\"), and (ii) one non-transferable contractual contingent value right (each, a \"CVR\"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the \"Offer Price\"). [continues to Footnote 2]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"[continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding, it was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":3.35,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001415889-25-020241","document":"form4-07242025_040701.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1783032/000141588925020241/form4-07242025_040701.xml","form_type":"4"}},{"id":1081819,"issuer":{"id":77243,"kind":"organization","name":"Elevation Oncology, Inc.","symbol":"ELEV"},"owners":[{"id":55791,"kind":"person","name":"Sandler Alan B.","position":1,"cik":"0001835966","reported_name":"Sandler Alan B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-24T16:40:04.000Z","date":"2025-07-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of June 8, 2025, by and among Elevation Oncology, Inc. (the \"Issuer\"), Concentra Biosciences, LLC (\"Parent\") and Concentra Merger Sub VI, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On July 23, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $0.36 per Share in cash (the \"Cash Amount\"), and (ii) one non-transferable contractual contingent value right (each, a \"CVR\"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the \"Offer Price\"). [continues to Footnote 2]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"[continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding, it was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":4.41,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001415889-25-020241","document":"form4-07242025_040701.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783032/000141588925020241/form4-07242025_040701.xml","form_type":"4"}},{"id":1117239,"issuer":{"id":77243,"kind":"organization","name":"Elevation Oncology, Inc.","symbol":"ELEV"},"owners":[{"id":55791,"kind":"person","name":"Sandler Alan B.","position":1,"cik":"0001835966","reported_name":"Sandler Alan B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-09T16:30:42.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 100% of the total shares on the one-year anniversary of the grant date, subject to the Reporting Person's provision of service to the Issuer on such vesting date."}],"balance_after":35000,"derivative":{"exercise_price":0.3051,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001415889-25-016272","document":"form4-06092025_040604.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783032/000141588925016272/form4-06092025_040604.xml","form_type":"4"}},{"id":1171874,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":55791,"kind":"person","name":"Sandler Alan B.","position":1,"cik":"0001835966","reported_name":"Sandler Alan B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-04-15T20:19:34.000Z","date":"2025-04-11","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All of the shares subject to the option vest on April 11, 2026."}],"balance_after":125000,"derivative":{"exercise_price":0.49,"expiration_date":"2035-04-11","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001415889-25-010692","document":"form4-04152025_080430.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000141588925010692/form4-04152025_080430.xml","form_type":"4"}},{"id":1296454,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":55791,"kind":"person","name":"Sandler Alan B.","position":1,"cik":"0001835966","reported_name":"Sandler Alan B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-01-23T23:11:49.000Z","date":"2025-01-21","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the option vest in 48 equal monthly installments beginning on February 21, 2025."}],"balance_after":100000,"derivative":{"exercise_price":1.65,"expiration_date":"2035-01-20","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001415889-25-001963","document":"form4-01232025_110146.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000141588925001963/form4-01232025_110146.xml","form_type":"4"}},{"id":1359379,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":55791,"kind":"person","name":"Sandler Alan B.","position":1,"cik":"0001835966","reported_name":"Sandler Alan B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-11-19T21:05:47.000Z","date":"2024-11-18","kind":"grant","planned":false,"acquired":true,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of the shares subject to the option vest on November 18, 2025 and 1/48th of the shares vest monthly thereafter."}],"balance_after":600000,"derivative":{"exercise_price":1.22,"expiration_date":"2034-11-17","underlying":"Common Stock","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0001415889-24-027181","document":"form4-11192024_091142.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000141588924027181/form4-11192024_091142.xml","form_type":"4"}},{"id":1438856,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":55791,"kind":"person","name":"Sandler Alan B.","position":1,"cik":"0001835966","reported_name":"Sandler Alan B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-08-07T21:23:49.000Z","date":"2024-08-05","kind":"grant","planned":false,"acquired":true,"shares":40400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the option vest in 36 equal monthly installments beginning on September 5, 2024."}],"balance_after":40400,"derivative":{"exercise_price":2.73,"expiration_date":"2034-08-04","underlying":"Common Stock","underlying_shares":40400},"source":{"system":"sec-edgar","filing":"0001415889-24-020932","document":"form4-08072024_090845.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000141588924020932/form4-08072024_090845.xml","form_type":"4"}},{"id":1476803,"issuer":{"id":77243,"kind":"organization","name":"Elevation Oncology, Inc.","symbol":"ELEV"},"owners":[{"id":55791,"kind":"person","name":"Sandler Alan B.","position":1,"cik":"0001835966","reported_name":"Sandler Alan B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-17T16:30:52.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 100% of the total shares on the one-year anniversary of the grant date, subject to the Reporting Person's provision of service to the Issuer on such vesting date."}],"balance_after":35000,"derivative":{"exercise_price":3.35,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001415889-24-017213","document":"form4-06172024_080649.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783032/000141588924017213/form4-06172024_080649.xml","form_type":"4"}},{"id":1602185,"issuer":{"id":77243,"kind":"organization","name":"Elevation Oncology, Inc.","symbol":"ELEV"},"owners":[{"id":55791,"kind":"person","name":"Sandler Alan B.","position":1,"cik":"0001835966","reported_name":"Sandler Alan B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-04T16:40:32.000Z","date":"2024-02-29","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 1/36th of the total shares monthly, beginning on March 29, 2024, subject to the Reporting Person's continued service to the Issuer on each vesting date."}],"balance_after":55000,"derivative":{"exercise_price":4.41,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001415889-24-006300","document":"form4-03042024_090327.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783032/000141588924006300/form4-03042024_090327.xml","form_type":"4"}},{"id":1672702,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":55791,"kind":"person","name":"Sandler Alan B.","position":1,"cik":"0001835966","reported_name":"Sandler Alan B.","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2024-01-23T20:37:36.000Z","date":"2024-01-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":65000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a Per Share Exercise Price that was equal to or greater than the Closing Consideration, but was less than the sum of the Closing Consideration and the maximum amount payable in respect of one CVR (the \"Maximum Total Consideration\"), was cancelled and converted into the right to receive a cash payment equal to (A) the excess of (x) the sum of (i) the Closing Consideration plus (ii) the actual Milestone Payment, if any, made in respect of one CVR over (y) the Per Share Exercise Price, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Such payment will be made if, and only if, a Milestone Payment is made in respect of a CVR and will be made at the same time the Milestone Payment is made to holders of CVRs. If the CVR is terminated or expires without payment, no payment will be made with respect to any such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a Per Share Exercise Price that was equal to or greater than the Closing Consideration, but was less than the sum of the Closing Consideration and the maximum amount payable in respect of one CVR (the \"Maximum Total Consideration\"), was cancelled and converted into the right to receive a cash payment equal to (A) the excess of (x) the sum of (i) the Closing Consideration plus (ii) the actual Milestone Payment, if any, made in respect of one CVR over (y) the Per Share Exercise Price, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":59.92,"expiration_date":"2032-11-06","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001140361-24-003530","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1576263/000114036124003530/form4.xml","form_type":"4"}},{"id":1672701,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":55791,"kind":"person","name":"Sandler Alan B.","position":1,"cik":"0001835966","reported_name":"Sandler Alan B.","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-01-23T20:37:36.000Z","date":"2024-01-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17021,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement and the Company Equity Plans (as such term is defined in the Merger Agreement), at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive a cash award of BMS in an amount equal to the product of the number of restricted stock units subject to such RSU immediately prior to the Effective Time and the last trading price of a share of Company Common Stock before the Effective Time (the \"Converted Cash Award\"). Following the Effective Time, the Converted Cash Award will be subject to the same terms and conditions applicable to such Issuer RSUs, including with respect to vesting."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-24-003530","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1576263/000114036124003530/form4.xml","form_type":"4"}},{"id":1672700,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":55791,"kind":"person","name":"Sandler Alan B.","position":1,"cik":"0001835966","reported_name":"Sandler Alan B.","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-01-23T20:37:36.000Z","date":"2024-01-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":52297,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of these restricted stock units (\"RSUs\") that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration in respect of each such RSU."}],"balance_after":17021,"source":{"system":"sec-edgar","filing":"0001140361-24-003530","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1576263/000114036124003530/form4.xml","form_type":"4"}},{"id":1672699,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":55791,"kind":"person","name":"Sandler Alan B.","position":1,"cik":"0001835966","reported_name":"Sandler Alan B.","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-01-23T20:37:36.000Z","date":"2024-01-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10547,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 8, 2023, among the Issuer, Bristol-Myers Squibb Company (\"BMS\"), and Vineyard Merger Sub Inc., a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\"), effective as of January 23, 2024 (such date and time of such Merger, the \"Effective Time\"), with the Issuer surviving the Merger as a wholly owned subsidiary of BMS."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Effective Time, each issued and outstanding share of common stock of the Issuer (\"Company Common Stock\") reported in this Form 4 was converted into the right to receive (A) $58.00 per share in cash (the \"Closing Consideration\") and (B) one contingent value right (a \"CVR\"), which represents the right to receive the Milestone Payment (as such term is defined in the CVR Agreement, which is itself defined in the Merger Agreement) (the consideration contemplated by (A) and (B), together, the \"Merger Consideration\"), without interest and subject to any withholding taxes."}],"balance_after":69318,"source":{"system":"sec-edgar","filing":"0001140361-24-003530","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1576263/000114036124003530/form4.xml","form_type":"4"}},{"id":1690983,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":55791,"kind":"person","name":"Sandler Alan B.","position":1,"cik":"0001835966","reported_name":"Sandler Alan B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-01-03T18:01:03.000Z","date":"2023-12-29","kind":"grant","planned":false,"acquired":true,"shares":17021,"price":58.75,"value":999983.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of Restricted Stock Units (RSUs). Shares will vest 25% annually on the anniversary of the grant date until fully vested."}],"balance_after":79318,"source":{"system":"sec-edgar","filing":"0001628280-24-000282","document":"wk-form4_1704322844.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1576263/000162828024000282/wk-form4_1704322844.xml","form_type":"4"}},{"id":1810614,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":55791,"kind":"person","name":"Sandler Alan B.","position":1,"cik":"0001835966","reported_name":"Sandler Alan B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-08-10T16:19:57.000Z","date":"2023-08-09","kind":"grant","planned":false,"acquired":true,"shares":22297,"price":37,"value":824989.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the one year anniversary of the grant date."}],"balance_after":62297,"source":{"system":"sec-edgar","filing":"0001628280-23-028871","document":"wk-form4_1691698785.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1576263/000162828023028871/wk-form4_1691698785.xml","form_type":"4"}},{"id":2122010,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":55791,"kind":"person","name":"Sandler Alan B.","position":1,"cik":"0001835966","reported_name":"Sandler Alan B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to buy)","published_at":"2022-11-08T18:00:19.000Z","date":"2022-11-07","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested."}],"balance_after":65000,"derivative":{"exercise_price":0,"expiration_date":"2032-11-06","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001214659-22-013305","document":"marketforms-57442.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1576263/000121465922013305/marketforms-57442.xml","form_type":"4"}},{"id":2122009,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":55791,"kind":"person","name":"Sandler Alan B.","position":1,"cik":"0001835966","reported_name":"Sandler Alan B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-11-08T18:00:19.000Z","date":"2022-11-07","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This represents a Restricted Stock Unit grant with a vesting period of 4 years that vests 25% annually from grant date and subject to the reporting persons continuously service to the issuer."}],"balance_after":40000,"source":{"system":"sec-edgar","filing":"0001214659-22-013305","document":"marketforms-57442.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1576263/000121465922013305/marketforms-57442.xml","form_type":"4"}},{"id":2220844,"issuer":{"id":4271,"kind":"organization","name":"Zai Lab Ltd","symbol":"ZLAB"},"owners":[{"id":55791,"kind":"person","name":"Sandler Alan B.","position":1,"cik":"0001835966","reported_name":"Sandler Alan B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Global Dev., Oncology"}}],"security":"Restricted Share Units","published_at":"2022-06-28T01:44:06.000Z","date":"2022-06-25","kind":"grant","acquired":true,"shares":73000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Share Unit represents a contingent right to receive one American Depositary Share (ADS), which represents ten Ordinary Shares of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Restricted Share Units vest in equal annual installments over four years beginning on 06/25/2023, the first anniversary of the date of grant. Vested shares will be delivered in the form of ADSs to the reporting person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Restricted Share Units vest in equal annual installments over four years beginning on 06/25/2023, the first anniversary of the date of grant. Vested shares will be delivered in the form of ADSs to the reporting person following vesting."}],"balance_after":73000,"derivative":{"underlying":"American Depositary Shares","underlying_shares":73000},"source":{"system":"sec-edgar","filing":"0000899243-22-024334","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1704292/000089924322024334/doc4.xml","form_type":"4"}},{"id":2303368,"issuer":{"id":4271,"kind":"organization","name":"Zai Lab Ltd","symbol":"ZLAB"},"owners":[{"id":55791,"kind":"person","name":"Sandler Alan B.","position":1,"cik":"0001835966","reported_name":"Sandler Alan B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Global Dev., Oncology"}}],"security":"Restricted Share Units","published_at":"2022-04-05T20:05:17.000Z","date":"2022-04-01","kind":"exercise","acquired":false,"shares":1060,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each Restricted Share Unit represents a contingent right to receive one ADS, which represents ten Ordinary Shares of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The Restricted Share Units vest in equal annual installments over five years beginning on 04/01/2022, the first anniversary of the date of grant. Vested shares will be delivered in the form of ADSs to the reporting person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The Restricted Share Units vest in equal annual installments over five years beginning on 04/01/2022, the first anniversary of the date of grant. Vested shares will be delivered in the form of ADSs to the reporting person following vesting."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (ADS) represents ten Ordinary Shares of the issuer."}],"balance_after":4240,"derivative":{"underlying":"American Depositary Shares","underlying_shares":1060},"source":{"system":"sec-edgar","filing":"0000899243-22-013696","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1704292/000089924322013696/doc4.xml","form_type":"4"}},{"id":2303367,"issuer":{"id":4271,"kind":"organization","name":"Zai Lab Ltd","symbol":"ZLAB"},"owners":[{"id":55791,"kind":"person","name":"Sandler Alan B.","position":1,"cik":"0001835966","reported_name":"Sandler Alan B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Global Dev., Oncology"}}],"security":"Restricted Share Units","published_at":"2022-04-05T20:05:17.000Z","date":"2022-04-01","kind":"grant","acquired":true,"shares":16692,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each Restricted Share Unit represents a contingent right to receive one ADS, which represents ten Ordinary Shares of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Restricted Share Units vest in equal annual installments over five years beginning on 04/01/2023, the first anniversary of the date of grant. Vested shares will be delivered in the form of ADSs to the reporting person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Restricted Share Units vest in equal annual installments over five years beginning on 04/01/2023, the first anniversary of the date of grant. Vested shares will be delivered in the form of ADSs to the reporting person following vesting."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (ADS) represents ten Ordinary Shares of the issuer."}],"balance_after":16692,"derivative":{"underlying":"American Depositary Shares","underlying_shares":16692},"source":{"system":"sec-edgar","filing":"0000899243-22-013696","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1704292/000089924322013696/doc4.xml","form_type":"4"}},{"id":2303366,"issuer":{"id":4271,"kind":"organization","name":"Zai Lab Ltd","symbol":"ZLAB"},"owners":[{"id":55791,"kind":"person","name":"Sandler Alan B.","position":1,"cik":"0001835966","reported_name":"Sandler Alan B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Global Dev., Oncology"}}],"security":"Stock Options (Right to Buy)","published_at":"2022-04-05T20:05:17.000Z","date":"2022-04-01","kind":"grant","acquired":true,"shares":87699,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The Stock Options are exercisable for ADSs. The number of securities underlying each option and the exercise price therefor are represented in ADSs. Each ADS represents ten Ordinary Shares of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Stock Options vest in equal annual installments over five years beginning on 04/01/2023, the first anniversary of the date of grant."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (ADS) represents ten Ordinary Shares of the issuer."}],"balance_after":87699,"derivative":{"exercise_price":45.47,"expiration_date":"2032-04-01","underlying":"American Depositary Shares","underlying_shares":87699},"source":{"system":"sec-edgar","filing":"0000899243-22-013696","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1704292/000089924322013696/doc4.xml","form_type":"4"}},{"id":2303365,"issuer":{"id":4271,"kind":"organization","name":"Zai Lab Ltd","symbol":"ZLAB"},"owners":[{"id":55791,"kind":"person","name":"Sandler Alan B.","position":1,"cik":"0001835966","reported_name":"Sandler Alan B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Global Dev., Oncology"}}],"security":"American Depositary Shares","published_at":"2022-04-05T20:05:17.000Z","date":"2022-04-01","kind":"exercise","acquired":true,"shares":1060,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (ADS) represents ten Ordinary Shares of the issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"ADSs acquired on vesting of Restricted Share Units. Each ADS represents ten Ordinary Shares of the issuer."}],"balance_after":28985,"source":{"system":"sec-edgar","filing":"0000899243-22-013696","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1704292/000089924322013696/doc4.xml","form_type":"4"}},{"id":2484846,"issuer":{"id":4271,"kind":"organization","name":"Zai Lab Ltd","symbol":"ZLAB"},"owners":[{"id":55791,"kind":"person","name":"Sandler Alan B.","position":1,"cik":"0001835966","reported_name":"Sandler Alan B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Global Dev., Oncology"}}],"security":"Ordinary Shares","published_at":"2021-12-03T23:29:52.000Z","date":"2021-12-01","kind":"tax_withholding","acquired":false,"shares":2075,"price":71.23,"value":147802.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were disposed of through a netting transaction to the issuer to cover taxes due."}],"balance_after":27925,"source":{"system":"sec-edgar","filing":"0001567619-21-021622","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1704292/000156761921021622/doc1.xml","form_type":"4"}},{"id":2756611,"issuer":{"id":4271,"kind":"organization","name":"Zai Lab Ltd","symbol":"ZLAB"},"owners":[{"id":55791,"kind":"person","name":"Sandler Alan B.","position":1,"cik":"0001835966","reported_name":"Sandler Alan B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Global Dev., Oncology"}}],"security":"Restricted Share Units","published_at":"2021-04-06T01:44:50.000Z","date":"2021-04-01","kind":"grant","acquired":true,"shares":5300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Share Unit represents a contingent right to receive one Ordinary Share of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Restricted Share Units vest in equal annual installments over five years beginning on 04/01/2022, the first anniversary of the date of grant. Vested shares will be delivered to the reporting person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Restricted Share Units vest in equal annual installments over five years beginning on 04/01/2022, the first anniversary of the date of grant. Vested shares will be delivered to the reporting person following vesting."}],"balance_after":5300,"derivative":{"underlying":"Ordinary Shares","underlying_shares":5300},"source":{"system":"sec-edgar","filing":"0000899243-21-014987","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1704292/000089924321014987/doc4.xml","form_type":"4"}},{"id":2756610,"issuer":{"id":4271,"kind":"organization","name":"Zai Lab Ltd","symbol":"ZLAB"},"owners":[{"id":55791,"kind":"person","name":"Sandler Alan B.","position":1,"cik":"0001835966","reported_name":"Sandler Alan B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Global Dev., Oncology"}}],"security":"Stock Options (Right to Buy)","published_at":"2021-04-06T01:44:50.000Z","date":"2021-04-01","kind":"grant","acquired":true,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Options vest in equal annual installments over five years beginning on 04/01/2022, the first anniversary of the date of grant."}],"balance_after":28000,"derivative":{"exercise_price":130.96,"expiration_date":"2031-04-01","underlying":"Ordinary Shares","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0000899243-21-014987","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1704292/000089924321014987/doc4.xml","form_type":"4"}}]}